RBC Capital analyst Brian Abrahams raised the firm’s price target on Galapagos (GLPG) to $28 from $27 and keeps a Sector Perform rating on the shares. The formal wind-down of the CAR-T program is not entirely surprising, but forces a re-think of how to appropriately value a company with a significant balance sheet and a biopharma-experienced leadership team but which is effectively a cash shell with unknown BD outcomes and some encumbrance from the Gilead (GILD) collaboration, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLPG:
- Leerink upgrades Galapagos on confidence after cell therapy exit
- Galapagos upgraded to Outperform from Market Perform at Leerink
- Galapagos NV to Wind Down Cell Therapy Business Following Strategic Review
- Galapagos intends to wind down cell therapy business
- Galapagos Appoints Fred Blakeslee as General Counsel